News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NovaBay Pharmaceuticals, Inc. (NBY) Announces Presentation Of Positive Data From Its Clinical Trial Of Auriclosene Irrigation Solution For Urinary Catheter Encrustation And Blockage


5/20/2014 10:35:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company developing non-antibiotic, topical antimicrobial products, today announced that Todd A. Linsenmeyer, M.D., Director of Urology, Kessler Institute for Rehabilitation, West Orange, NJ, and one of the principal investigators of a multi-center clinical study, will present results showing significant benefits from a new catheter irrigation solution. In the trial, 9 of 14 catheters collected from patients that irrigated twice a week with saline solution, the only current treatment option, became completely encrusted.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES